I don't understand your anger against NWBO, I could post many positives that you want to ignore, I own both but share NWBO because imo they have better results, better manufacturing facilties, working closely with FDA and EU regulators, and testimonies from many with different cancers treated by DcVAx and back to normal lives after being on hospice. Those are facts. I suggest you buy 1000 shares, your risk is 5,000 but think of the upside ! Thats probably chump change for you but do what you feel good about. Have a good Thanksgiving,
FACTS don't lie like some posters do.
UCLA and DcVAX from NWBO.
In Germany, the Company
has also received approval of a 5-year Hospital Exemption for the treatment of
all gliomas (brain cancer) patients outside the clinical trial.
As a result, DCVax-L can potentially address all GBM patients,
and all types and grades of glioma patients - not just a small fraction of GBM
patients, as is the case with products aimed at just one or a few tumor targets,
or one patient type. What is needed is a new and better treatment for all GBM
patients - a new standard of care."
(Reuters) - Neil Woodford, one of Britain's most famous fund managers due to his strong track record, has seen his new CF Woodford Equity Income fund given a 'Bronze' rating by fund analysts Morningstar.
It is the first time Morningstar has ranked the fund since it was launched to much fanfare earlier this year, after Woodford left Invesco Perpetual to start up his own company, WoodfordInvestment Management.
"The strategy of this fund is clear, and aims to generate a positive capital return in the long term and grow the income whilst offering capital preservation," Morningstar said in a statement on Tuesday.
"He has proven himself willing to stick to his strategy even during periods of poor performance. As a result, his long-term track record, which encompasses numerous market cycles, is strong," they added. (Reporting by Simon Jessop; editing by Carolyn Cohn)
Eight months after Neil Woodford announced his shock departure from Invesco Perpetual, investors have a chance to entrust the UK equity income guru with their cash once more. On June 19, CF Woodford Equity Income Fund will open its doors to the public, although Woodford fanatics can pre-order the fund through various fund supermarkets today. Woodford has promised investors that the new fund’s portfolio will feature many of the names he has held over the last 25 years at Invesco. The new Woodford fund will be targeting a 4% yield with aims to grow the yield to a “high single digit”. As well as key players investors will be familiar with such as pharmaceutical stocks and tobacco companies there will be an allocation to unlisted equities, particularly with a technology and innovation theme. Unlisted and micro-cap equities is a sector that Woodford feels passionate about and it is widely expected that he will launch a private equity fund in the near future. A second fund launch has been referenced by Woodford himself, although no date or portfolio information has been released. While Woodford’s performance is indubitable, many of his core holdings have rallied significantly since he last bought them. Names such as British American Tobacco (BATS) have rallied 112% over the past five years, and pharmaceuticals – which Woodford championed when nobody else would, have rallied too. GlaxoSmithKline (GSK) is up 53% over five years. Woodford’s style has served him and his investors extremely well over the last two decades – but because of this, many of the holdings we have come to expect in his portfolio will not be as cheap as they were last time he bought them. And if they are not as cheap, investors should not expect them to offer the same level of returns. Speaking at a recent dinner Woodford said that while he appreciated the market had rallied he still considered there to be value in the names he loves. “This is not a 2000 stock market parallel where everything is overvalued. There are some remarkably overvalued sectors, but that doesn’t mean there isn’t value to be found,” he said. Woodford himself says this is “Woodford Funds as a company will be a very different offering – but expect business as usual when it comes to stock selection and the running of the new income fund”.
Just showing the facts on NWBO, watch this amazing video,
"The UCLA Brian Tumor Program continues to shine as a beacon of hope, carrying a record of patients with brain tumors living longer than patients treated at any other hospital. Our personalized brain cancer vaccine, DCVax, is the first of its kind and is currently in Phase III clinical trials in 46 centers throughout America. It is on the road to FDA approval as well as clinical trials throughout Europe. Using this vaccine, we are harnessing the patient’s immune system, genetics, pathology, brain mapping and a wide database of bioinformatics to optimize outcomes.
We welcome you to UCLA Neurosurgery!
—Neil A. Martin
Chairman and W. Eugene Stern Professor in Neurosurgery
UCLA Department of Neurosurgery"
Taken from their website...Impressive for NWBO
Watch these videos on brain cancer patients cured by NWBO vaccine !